在扩展阶段小细胞肺癌中,在维持免疫疗法后恢复化疗超越进展后重新开始化疗
Roxana-Andreea Rahnea-Nita1,2, Radu-Valeriu Toma1,3, Valentin Titus Grigorean4,5
18th Clinical Department-Radiology, Oncology and Hematology, Faculty of Medicine, "Carol Davila" University of Medicine and Phamacy, 020021 Bucharest, Romania.
Medicina (Kaunas, Lithuania)
|August 29, 2024
概括
这项案例研究表明,在免疫疗法失败后,重启化疗可能是扩散阶段小细胞肺癌患者的可行选择. 埃波素α有效地控制了贫血,使治疗能够继续进行.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
背景情况:
- 小细胞肺癌 (SCLC) 具有侵略性,预后不佳.
- 对SCLC的2年生存率大约为8%.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
